North Kingstown, RI, United States of America

Cahil McGovern

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Cahil McGovern: Innovator in Ophthalmic Disorders Treatment

Introduction

Cahil McGovern is a notable inventor based in North Kingstown, Rhode Island, who has made significant contributions to the field of ophthalmology. With a total of four patents to his name, McGovern is recognized for his innovative approaches to treating various ophthalmic disorders.

Latest Patents

Among his latest patents is the groundbreaking work on the use of encapsulated cell therapy for the treatment of ophthalmic disorders. This patent describes methods and devices designed for the long-term treatment of conditions such as retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma, and macular telangiectasia. The encapsulated cell therapy (ECT) devices developed by McGovern secrete biologically active molecules, providing new avenues for effective treatment.

Career Highlights

Cahil McGovern has established himself as a key figure in the medical technology sector, particularly through his work at Neurotech USA, Inc. His innovative research and development efforts have positioned him at the forefront of advancements in ophthalmic therapies.

Collaborations

Throughout his career, McGovern has collaborated with esteemed colleagues, including Weng Tao and Konrad A Kauper. These partnerships have further enhanced the impact of his work in the field.

Conclusion

Cahil McGovern's contributions to the treatment of ophthalmic disorders through encapsulated cell therapy highlight his role as a leading inventor in the medical technology industry. His innovative patents and collaborations continue to pave the way for advancements in patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…